Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1972 1
1974 2
1975 2
1976 1
1977 2
1978 4
1979 4
1980 2
1984 1
1988 1
1990 1
1992 1
1993 1
1995 2
1997 2
1998 2
1999 1
2000 3
2001 1
2002 2
2003 2
2004 1
2006 1
2008 1
2010 7
2011 5
2012 6
2013 5
2014 21
2015 23
2016 28
2017 26
2018 26
2019 9
2020 25
2021 21
2022 20
2023 20
2024 11
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Results by year

Filters applied: . Clear all
Page 1
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.
Lapitz A, Azkargorta M, Milkiewicz P, Olaizola P, Zhuravleva E, Grimsrud MM, Schramm C, Arbelaiz A, O'Rourke CJ, La Casta A, Milkiewicz M, Pastor T, Vesterhus M, Jimenez-Agüero R, Dill MT, Lamarca A, Valle JW, Macias RIR, Izquierdo-Sanchez L, Pérez Castaño Y, Caballero-Camino FJ, Riaño I, Krawczyk M, Ibarra C, Bustamante J, Nova-Camacho LM, Falcon-Perez JM, Elortza F, Perugorria MJ, Andersen JB, Bujanda L, Karlsen TH, Folseraas T, Rodrigues PM, Banales JM. Lapitz A, et al. Among authors: o rourke cj. J Hepatol. 2023 Jul;79(1):93-108. doi: 10.1016/j.jhep.2023.02.027. Epub 2023 Mar 1. J Hepatol. 2023. PMID: 36868481 Free PMC article.
miR-21-5p promotes NASH-related hepatocarcinogenesis.
Rodrigues PM, Afonso MB, Simão AL, Islam T, Gaspar MM, O'Rourke CJ, Lewinska M, Andersen JB, Arretxe E, Alonso C, Santos-Laso Á, Izquierdo-Sanchez L, Jimenez-Agüero R, Eizaguirre E, Bujanda L, Pareja MJ, Prip-Buus C, Banales JM, Rodrigues CMP, Castro RE. Rodrigues PM, et al. Among authors: o rourke cj. Liver Int. 2023 Oct;43(10):2256-2274. doi: 10.1111/liv.15682. Epub 2023 Aug 3. Liver Int. 2023. PMID: 37534739
TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
Esparza-Baquer A, Labiano I, Sharif O, Agirre-Lizaso A, Oakley F, Rodrigues PM, Zhuravleva E, O'Rourke CJ, Hijona E, Jimenez-Agüero R, Riaño I, Landa A, La Casta A, Zaki MYW, Munoz-Garrido P, Azkargorta M, Elortza F, Vogel A, Schabbauer G, Aspichueta P, Andersen JB, Knapp S, Mann DA, Bujanda L, Banales JM, Perugorria MJ. Esparza-Baquer A, et al. Among authors: o rourke cj. Gut. 2021 Jul;70(7):1345-1361. doi: 10.1136/gutjnl-2019-319227. Epub 2020 Sep 9. Gut. 2021. PMID: 32907830 Free PMC article.
Reply.
Santos AF, Evans E, O'Rourke C, Bahnson HT, Lack G. Santos AF, et al. Among authors: o rourke c. J Allergy Clin Immunol. 2022 Mar;149(3):1129-1131. doi: 10.1016/j.jaci.2021.12.766. Epub 2022 Jan 6. J Allergy Clin Immunol. 2022. PMID: 35000772 No abstract available.
Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
O'Rourke CJ, Salati M, Rae C, Carpino G, Leslie H, Pea A, Prete MG, Bonetti LR, Amato F, Montal R, Upstill-Goddard R, Nixon C, Sanchon-Sanchez P, Kunderfranco P, Sia D, Gaudio E, Overi D, Cascinu S, Hogdall D, Pugh S, Domingo E, Primrose JN, Bridgewater J, Spallanzani A, Gelsomino F, Llovet JM, Calvisi DF, Boulter L, Caputo F, Lleo A, Jamieson NB, Luppi G, Dominici M, Andersen JB, Braconi C. O'Rourke CJ, et al. Gut. 2024 Feb 23;73(3):496-508. doi: 10.1136/gutjnl-2023-330748. Gut. 2024. PMID: 37758326 Free PMC article.
Immunogenomics of cholangiocarcinoma.
Gehl V, O'Rourke CJ, Andersen JB. Gehl V, et al. Among authors: o rourke cj. Hepatology. 2025 Aug 1;82(2):522-539. doi: 10.1097/HEP.0000000000000688. Epub 2023 Nov 16. Hepatology. 2025. PMID: 37972940 Review.
Intrahepatic cholangiocarcinoma PANoptosidy.
O'Rourke CJ, Andersen JB. O'Rourke CJ, et al. Hepatology. 2025 May 8. doi: 10.1097/HEP.0000000000001398. Online ahead of print. Hepatology. 2025. PMID: 40338156 No abstract available.
Molecular Targets in Cholangiocarcinoma.
O'Rourke CJ, Munoz-Garrido P, Andersen JB. O'Rourke CJ, et al. Hepatology. 2021 Jan;73 Suppl 1:62-74. doi: 10.1002/hep.31278. Epub 2020 Dec 3. Hepatology. 2021. PMID: 32304327 Review.
Epigenome Remodeling in Cholangiocarcinoma.
O'Rourke CJ, Lafuente-Barquero J, Andersen JB. O'Rourke CJ, et al. Trends Cancer. 2019 Jun;5(6):335-350. doi: 10.1016/j.trecan.2019.05.002. Epub 2019 Jun 4. Trends Cancer. 2019. PMID: 31208696 Review.
E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment.
González-Romero F, Mestre D, Aurrekoetxea I, O'Rourke CJ, Andersen JB, Woodhoo A, Tamayo-Caro M, Varela-Rey M, Palomo-Irigoyen M, Gómez-Santos B, de Urturi DS, Núñez-García M, García-Rodríguez JL, Fernández-Ares L, Buqué X, Iglesias-Ara A, Bernales I, De Juan VG, Delgado TC, Goikoetxea-Usandizaga N, Lee R, Bhanot S, Delgado I, Perugorria MJ, Errazti G, Mosteiro L, Gaztambide S, Martinez de la Piscina I, Iruzubieta P, Crespo J, Banales JM, Martínez-Chantar ML, Castaño L, Zubiaga AM, Aspichueta P. González-Romero F, et al. Among authors: o rourke cj. Cancer Res. 2021 Jun 1;81(11):2874-2887. doi: 10.1158/0008-5472.CAN-20-2052. Epub 2021 Mar 26. Cancer Res. 2021. PMID: 33771899
265 results